CClinicalTrials.gg
CompletedNCT03097523NSBRIUpdated Aug 16, 2017

Mitigating Cephalad Fluid Shifts: A NSBRI Study

An interventional study of Custom Thigh Cuff in Intracranial Pressure, sponsored by Saint John's Cancer Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2017-08-16.

Sponsored by Saint John's Cancer Institute · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 89 Years
Sex
All
01

Study summary

This is a feasibility study to determine optimal thigh cuff design using a cephalad fluid shift protocol in patients who have an intraventricular catheter (such as Ommaya reservoir) placed for the delivery of central nervous system chemotherapy or for diagnosing potential elevation of ICP and monitoring its progression as part of standard medical care.

02

Conditions studied

  • Intracranial Pressure

Keywords

  • NSBRI
03

In context

Lead sponsor

Saint John's Cancer Institute is the lead sponsor of 22 studies on the registry; 1 is open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female, 18-89 years old
  • Willing and able to provide informed consent
  • Patients who have an intraventricular catheter placed for the delivery of central nervous system chemotherapy or for diagnosing potential elevation of ICP and monitoring its progression as part of standard medical care
  • KPS ≥ 70
  • For patients on active anti-cancer (intra-thecal or IV) therapy, must be at least 2 weeks since last treatment; oral therapy is permitted

Exclusion criteria

Exclusion Criteria:

  • Less than 2 weeks since any prior surgery
  • ICP > 20 mmHg that cannot be clinically stabilized
  • Pregnant (Note: women of child-bearing potential must have a negative urine pregnancy test; women who are not of child-bearing potential are defined as: post-menopausal, age > 55 years with cessation of menses for 12 or more months; or less than 55 years with postmenopausal status confirmed by follicle-stimulating hormone in the post-menopausal range; or who have had a hysterectomy, bilateral salpingectomy, or bilateral oophorectomy)
  • Existing cardiovascular disease, diabetes, syncope, ocular disease that, in the opinion of the investigator, may confound the study results
  • Uncontrolled neurological symptoms such as headache, nausea or vomiting that, in the opinion of the investigator, will limit the patient's ability to participate in the study
  • Injury, trauma, venous thromboembolism, peripheral arterial disease or any condition that, in the opinion of the investigator, will prevent the subject from tolerating the application of a thigh cuff; history of treated DVT is permitted
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Study Arm

    Patients with intraventricular catheter meeting eligibility criteria will undergo the following procedures: * Blood pressure, heart rate, electrocardiogram and Intracranial Pressure (ICP) monitoring after standard of care procedures are completed * Continuous ICP monitoring using a disposable pressure transducer (i.e., TruWaveTM) * Sequential placement in an upright, seated, supine 0°, and supine 15° head down tilt (HDT) positions for approximately 15 minutes for stabilization, followed by: Non-invasive ICP, intra-ocular pressure (IOP) assessment, femoral vascular ultrasound, jugular vascular ultrasound, and assessment of adverse events

    Device: Custom Thigh Cuff

Interventions

  • DeviceCustom Thigh Cuff

    The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.

06

What researchers measure

Primary outcomes

  1. Changes in intracranial pressure using cerebral and cochlear fluid pressure (CCFP) analyser and a disposable pressure transducer

    Noninvasive and invasive ICP monitoring following standard of care procedures requiring access to ventricular catheter

    Time frame: 20 minutes

07

Study locations

1 site
  • John Wayne Cancer Institute at Providence Saint John's Health Center
    Santa Monica, California 90404, United States
08

References and documents

Individual participant data

Plan to share: No — Data transfers or sharing is restricted to those JWCI study personnel identified on the site delegation log and/or per data use agreements. Data will be provided to the study sponsor.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03097523
Lead sponsor
Saint John's Cancer Institute
Collaborators
National Space Biomedical Research Institute
Responsible party
Sponsor
First posted
Mar 31, 2017
Start date
Jan 1, 2017
Primary completion
May 31, 2017
Completion
May 31, 2017
Last update
Aug 16, 2017

Study contacts

Santosh Kesari, MD, PhD
principal investigator · Saint John's Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion